news
Alzheimer’s therapeutics market to reach $6.8 billion by 2032
A large patient population and limited treatment options are expected to expand the Alzheimer’s therapeutics market at a CAGR of 9.3 percent, suggested a report.
List view / Grid view
Avid Radiopharmaceuticals
news
FDA approves Amyvid™
6 April 2012 | By Eli Lilly and Company
Amyvid is the first and only radioactive diagnostic agent approved for PET imaging of beta-amyloid neuritic plaques in the living brain...
news
Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid(TM) (Florbetapir) NDA
20 January 2011 | By Eli Lilly and Company
The U.S. FDA Peripheral and Central Nervous System Drugs Advisory Committee decided today that it could not recommend approval of Amyvid™ (florbetapir) at this time...
